1. Comparison of Liver Transplantation and Liver Resection for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus Type I and Type II
- Author
-
Bing Yang, Ningning Zhang, Yan Xie, Xin Sun, Wei Lu, Zheng Lu Wang, Li Zhang, Wen Tao Jiang, Yi Bo Qiu, Jie Gu, Ying Wu, Ya Min Zhang, Yu Xin Liu, Da Zhi Tian, Yan Qu, Ji San Sun, Ze Yu Wang, Ya Wei Du, Tian Qiang Song, Jia Yu Lv, and Qingjun Guo
- Subjects
Adult ,Male ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Hepatocellular carcinoma ,medicine.medical_treatment ,Portal vein ,Subgroup analysis ,030204 cardiovascular system & hematology ,Liver transplantation ,Gastroenterology ,portal vein tumor thrombus ,Resection ,03 medical and health sciences ,0302 clinical medicine ,Tumor thrombus ,Risk Factors ,Internal medicine ,medicine ,Hepatectomy ,Humans ,In patient ,Retrospective Studies ,Tumor size ,liver transplantation ,business.industry ,Portal Vein ,Liver Neoplasms ,Thrombosis ,General Medicine ,Middle Aged ,medicine.disease ,Prognosis ,Oncology ,030220 oncology & carcinogenesis ,liver resection ,Female ,Original Article ,alpha-Fetoproteins ,business - Abstract
Purpose The aim of this study was to compare the efficacy of liver transplantation (LT) and liver resection (LR) for hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT) and to investigate risk factors affecting prognosis. Materials and methods A total of 94 HCC patients with PVTT type I (segmental PVTT) and PVTT type II (lobar PVTT) were involved and divided into LR (n=47) and LT groups (n=47). Recurrence-free survival (RFS) and overall survival (OS) were compared before and after inverse probability of treatment weighting (IPTW). Prognostic factors for RFS and OS were explored. Results Two treatment groups were well-balanced using IPTW. In the entire cohort, LT provided a better prognosis than LR. Among patients with PVTT type I, RFS was better with LT (p=0.039); OS was not different significantly between LT and LR (p=0.093). In subgroup analysis of PVTT type I patients with α-fetoprotein (AFP) levels >200 ng/mL, LT elicited significantly longer median RFS (18.0 months vs. 2.1 months, p=0.022) and relatively longer median OS time (23.6 months vs. 9.8 months, p=0.065). Among patients with PVTT type II, no significant differences in RFS and OS were found between LT and LR (p=0.115 and 0.335, respectively). Multivariate analyses showed treatment allocation (LR), tumor size (>5 cm), AFP and aspartate aminotransferase (AST) levels to be risk factors of RFS and treatment allocation (LR), AFP and AST as risk factors for OS. Conclusion LT appeared to afford a better prognosis for HCC with PVTT type I than LR, especially in patients with AFP levels >200 ng/mL.
- Published
- 2020